小児外科医による小児がんに対するトランスレーショナルリサーチ

1)

2)

3)

4)

5)

6)

7)

8)

9)

10)

11)

12)

13)

14)

15)

16)

17)

Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A,

Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS,

Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins

TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM,

Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg

R, Schleiermacher G, Molenaar JJ and Maris JM. Relapsed neuroblastomas show frequent RAS-MAPK

pathway mutations. Nat Genet. 47 : 864-871, 2015.

Tanaka T, Higashi M, Kimura K, Wakao J, Fumino S, Iehara T, Hosoi H, Sakai T and Tajiri T. MEK inhibitors

as a novel therapy for neuroblastoma : Their in vitro effects and predicting their efficacy. J Pediatr Surg. 51 :

2074-2079, 2016.

Tanaka T, Togashi Y, Takeuchi Y, Higashi M, Fumino S and Tajiri T. Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma.

Pediatr Surg Int. 37 : 287-291, 2021.

Takeuchi Y, Tanaka T, Higashi M, Fumino S, Iehara T, Hosoi H, Sakai T and Tajiri T. In vivo effects of shortand long-term MAPK pathway inhibition against neuroblastoma. J Pediatr Surg. 53 : 2454-2459, 2018.

Togashi Y, Tanaka T, Takemoto M, Takeuchi Y, Higashi M, Fumino S and Tajiri T. Anti-relapse effect of

trametinib on a local minimal residual disease neuroblastoma mouse model. J Pediatr Surg. 56 : 1233-1239,

2021.

Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S and Ajani JA. A Novel YAP1

Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in

Esophageal Adenocarcinoma. Mol Cancer Ther. 17 : 443-454, 2018.

Takemoto M, Tanaka T, Tsuji R, Togashi Y, Higashi M, Fumino S and Tajiri T. The synergistic antitumor

effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.

Biochem Biophys Res Commun. 570 : 41-46, 2021.

Kimura K, Kishida T, Wakao J, Tanaka T, Higashi M, Fumino S, Aoi S, Furukawa T, Mazda O and Tajiri T.

Tumor-homing effect of human mesenchymal stem cells in a TH-MYCN mouse model of neuroblastoma. J

Pediatr Surg. 51 : 2068-2073, 2016.

Väänänen HK. Mesenchymal stem cells. Ann Med. 37 : 469-479, 2005.

Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM. Targeted expression of MYCN causes

neuroblastoma in transgenic mice. Embo j. 16 : 2985-2995, 1997.

Tatsuta K, Tanaka S, Tajiri T, Shibata S, Komaru A, Ueda Y, Inoue M, Hasegawa M, Suita S, Sueishi K,

Taguchi T and Yonemitsu Y. Complete elimination of established neuroblastoma by synergistic action of

gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther. 16 : 240-251,

2009.

Maniwa J, Fumino S, Kimura K, Tanaka T, Higashi M, Kishida T, Mazda O and Tajiri T. Novel mesenchymal

stem cell delivery system as targeted therapy against neuroblastoma using the TH-MYCN mouse model. J

Pediatr Surg. 54 : 2600-2605, 2019.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca

JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL,

Maris JM and Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for

neuroblastoma. N Engl J Med. 363 : 1324-1334, 2010.

Voeller J and Sondel PM. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.

J Pediatr Hematol Oncol. 41 : 163-169, 2019.

Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A,

Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri

T and Nakagawara A. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07 : a

report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG). Int J Clin Oncol. 23 :

965-973, 2018.

Tohme S, Simmons RL and Tsung A. Surgery for Cancer : A Trigger for Metastases. Cancer Res. 77 :

1548-1552, 2017.

Alieva M, van Rheenen J and Broekman MLD. Potential impact of invasive surgical procedures on primary

218

小児外科医による小児がん基礎研究

tumor growth and metastasis. Clin Exp Metastasis. 35 : 319-331, 2018.

18) Inoue M, Tsuchiya Y, Koike N, Umemura Y, Inokawa H, Togashi Y, Maniwa J, Higashi M, Fumino S, Tajiri T

and Yagita K. Enhanced metastatic growth after local tumor resection in the presence of synchronous

metastasis in a mouse allograft model of neuroblastoma. Pediatr Surg Int. 35 : 1403-1411, 2019.

（特に重要な文献については，番号をゴシック体で表記している．）

著者プロフィール

田尻 達郎（たじり たつろう）

九州大学教授（大学院医学研究院小児外科学）．医学博士

◆略歴 1963 年長崎県に生まれる．1988 年九州大学医学部卒業．1995 年同大学院医学研究科博士

課程修了．1998 年九州大学大学院医学研究院小児外科学助手．2001 年米国フィラデル

フィアこども病院研究員．2003 年九州大学大学院医学研究院小児外科学講師．2006 年九

州大学大学院医学研究院小児外科学准教授．2011 年京都府立医科大学大学院小児外科学教

授．2021 年より現職．

◆研究テーマと抱負 分子生物学的手法を用いた小児固形悪性腫瘍の発生，進展のメカニズムの解

明，及び，新規治療法の開発．小児がんを中心とした小児外科患者さんに対する 20 年の

QOL を重視したテーラーメード型治療の推進，実行を目指しています．

◆趣味 スポーツ鑑賞，映画鑑賞

ほか２名

219

Translational Research for Childhood Cancer Conducted by Surgeons

Tatsuro TAJIRI1)2), Tomoko TANAKA2) and Shigehisa FUMINO2)

1)

2)

Department of Pediatric Surgery, Kyusyu University

Department of Pediatric Surgery, Kyoto Prefectural University of Medicine

Abstract

In the multidisciplinary therapy for childhood cancer, surgeons mainly play a role of surgical

resection as a local therapy. When the surgeons gain a better understanding of total management of

cancer therapy and tumor biology, they could conduct the advanced tailor-made therapy including

QOL-based surgery, and organ-preserving surgery. Therefore, the translational research for

childhood cancer conducted by surgeons is meaningful and could lead the development of the surgical

treatment.

In this manuscript, we introduced our history of translational researches for neuroblastoma, the

most common extracranial solid tumor in children. Briefly, weʼve been doing research on 1) MEK

inhibitor which inhibit MAPK pathway, as a novel molecurar-targeted therapy for MAPK-activated

neuroblastoma, 2) the Drug Delivery System using tumor-homing ability of mesenchymal stem cells in

a transgenic TH-MYCN mouse model of neuroblastoma, 3) the impact of local tumor resection on

metastatic lesions in newly established MYCN transgenic allograft mouse model. Through these

research, we are aiming to develop novel multi-modality therapy for high-risk neuroblastoma from

the perspective of pediatric surgeons.

It is of importance that young pediatric surgeons make these basic research by themselves and

understand the current standard of care for pediatric tumors and the biology of tumors as well as

surgical technique to achieve the optimal surgery in the treatment of pediatric tumors.

Key words : pediatric surgery, pediatric cancer, neuroblastoma, translational research

...